Ranitidine (oral): Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 1: Line 1:
<small>'''''Synonyms / Brand Names: Ranitidine hydrochloride, Ranitidine HCL, Ranitidine Base, Rantidine HCL, Alquen, Alter-H2, Alvidina, Apo-Ranitidin, Artomil, Azuranit, Coralen, Digestosan, Ergan, Esofex, Fendibina, Gastrial, Gastridina, Gastrolav, Gastrosedol, Kuracid, Label, Lake, Logat, Melfax, Microtid, Mideran, Neugal, Noctone, Noktome, Normon, Novo-Radinine, Nu-Ranit, Pep-Rani, Ptinolin, Quadrin, Quantor, Radin, Ran H2, Ran Lich, Rani 2, Rani AbZ, Rani-BASF, Rani-Puren, Rani-Q, Rani-Sanorania, Rani-nerton, Raniben, Raniberl, Raniberta, Ranibloc, Ranic, Ranicux, Ranidil, Ranidin, Ranidine, Ranidura, Ranifur, Ranigasan, Ranigast, Ranigen, Ranilonga, Ranimerck, Raniogas, Raniplex, Ranisan, Ranitab, Ranitic, Ranitidin, Ranitidin 1A Pharma, Ranitidin AL, Ranitidin AWD, Ranitidin Arcana, Ranitidin Atid, Ranitidin Basics, Ranitidin Duncan, Ranitidin Dyna, Ranitidin Helvepharm, Ranitidin Heumann, Ranitidin Hexal, Ranitidin Merck, Ranitidin Millet, Ranitidin NM, Ranitidin Normon, Ranitidin PB, Ranitidin Stada, Ranitidin von ct, Ranitidin-Cophar, Ranitidin-Isis, Ranitidin-ratiopharm, Ranitidina Tamarang, Ranitidina predilu Grif, Ranitiget, Ranitin, Ranitine, Ranobel, Rantacid, Ranuber, Raticina, Regalil, Renatac, Rozon, Rubiulcer, Santanol, Serviradine, Sostril, Tanidina, Taural, Terposen, Toriol, Trigger, Ulcecur, Ulcex, Ulcirex, Ulcodin, Ulcolind Rani, Ulsaven, Ultidine, Viserul, Zandid, Zantac, Zantac 150, Zantac 75, Zantac In Plastic Container, Zantarac, Zantic
''''' </small>
{{DrugProjectFormSinglePage
{{DrugProjectFormSinglePage
|authorTag=
|authorTag={{Ammu}}
 
|genericName=Ranitidine
 
|aOrAn=a
<!--Overview-->
|drugClass=antacid
 
|indicationType=treatment
|genericName=
|indication=relieves heartburn associated with acid indigestion and sour stomach
 
prevents heartburn associated with acid indigestion and sour stomach brought on by certain foods and beverages
 
|adverseReactions=headache, constipation, diarrhoea, abdominal pain
 
|blackBoxWarningTitle=Title
|aOrAn=
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
 
a
 
|drugClass=
 
 
 
|indication=
 
 
 
|hasBlackBoxWarning=
 
Yes
 
|adverseReactions=
 
 
 
<!--Black Box Warning-->
 
|blackBoxWarningTitle=
Title
 
|blackBoxWarningBody=
<i><span style="color:#FF0000;">ConditionName: </span></i>


* Content
* Content
Line 45: Line 16:


<!--FDA-Labeled Indications and Dosage (Adult)-->
<!--FDA-Labeled Indications and Dosage (Adult)-->
 
|fdaLIADAdult=* Relieves heartburn associated with acid indigestion and sour stomach
|fdaLIADAdult=
* Prevents heartburn associated with acid indigestion and sour stomach brought on by certain foods and beverages
 
*Ranitidine 150 mg (as ranitidine hydrochloride 168 mg)
=====Condition1=====
|offLabelAdultGuideSupport======Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
* Dosing Information
 
:* Dosage
 
=====Condition3=====
 
* Dosing Information
 
:* Dosage
 
=====Condition4=====
 
* Dosing Information
 
:* Dosage
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
 
|offLabelAdultGuideSupport=
 
=====Condition1=====


* Developed by:  
* Developed by:  
Line 95: Line 36:


<!--Non–Guideline-Supported Use (Adult)-->
<!--Non–Guideline-Supported Use (Adult)-->
 
|offLabelAdultNoGuideSupport======Condition1=====
|offLabelAdultNoGuideSupport=
 
=====Condition1=====


* Dosing Information
* Dosing Information
Line 111: Line 49:


<!--FDA-Labeled Indications and Dosage (Pediatric)-->
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
 
|fdaLIADPed======Condition1=====
|fdaLIADPed=
 
=====Condition1=====


* Dosing Information
* Dosing Information
Line 127: Line 62:


<!--Guideline-Supported Use (Pediatric)-->
<!--Guideline-Supported Use (Pediatric)-->
 
|offLabelPedGuideSupport======Condition1=====
|offLabelPedGuideSupport=
 
=====Condition1=====


* Developed by:  
* Developed by:  
Line 147: Line 79:


<!--Non–Guideline-Supported Use (Pediatric)-->
<!--Non–Guideline-Supported Use (Pediatric)-->
 
|offLabelPedNoGuideSupport======Condition1=====
|offLabelPedNoGuideSupport=
 
=====Condition1=====


* Dosing Information
* Dosing Information
Line 161: Line 90:


<!--Contraindications-->
<!--Contraindications-->
 
|contraindications=* Condition1
|contraindications=
 
* Condition1


<!--Warnings-->
<!--Warnings-->
|warnings======Allergy alert=====
* Do not use if you are allergic to ranitidine or other acid reducers
* Do not use if you have trouble or pain swallowing food, vomiting with blood, or bloody or black stools. These may be signs of a serious condition.
* with other acid reducers
* if you have kidney disease, except under the advice and supervision of a doctor
* Ask a doctor before use if you have
:* frequent chest pain
:* frequent wheezing, particularly with heartburn
unexplained weight loss
:* nausea or vomiting
:* stomach pain
had heartburn over 3 months. This may be a sign of a more serious condition.
:* heartburn with lightheadedness, sweating, or dizziness
chest pain or shoulder pain with shortness of breath; sweating; pain spreading to arms, neck or shoulders; or lightheadedness
* Stop use and ask a doctor if your heartburn continues or worsens
you need to take this product for more than 14 days
* If pregnant or breast-feeding, ask a health professional before use.
* Keep out of reach of children.


|warnings=
|useInPregnancyFDA=* '''Pregnancy Category'''
 
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
* Description
 
====Precautions====
 
* Description
 
<!--Adverse Reactions-->
 
<!--Clinical Trials Experience-->
 
|clinicalTrials=
 
There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
 
=====Cardiovascular=====
 
 
 
 
=====Digestive=====
 
 
 
 
=====Endocrine=====
 
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
 
=====Metabolic and Nutritional=====
 
 
 
 
=====Musculoskeletal=====
 
 
 
 
=====Neurologic=====
 
 
 
 
=====Respiratory=====
 
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
 
=====Special Senses=====
 
 
 
 
=====Urogenital=====
 
 
 
 
=====Miscellaneous=====
 
 
 
<!--Postmarketing Experience-->
 
|postmarketing=
 
There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
=====Cardiovascular=====
 
 
 
=====Digestive=====
 
 
 
=====Endocrine=====
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
=====Metabolic and Nutritional=====
 
 
 
=====Musculoskeletal=====
 
 
 
=====Neurologic=====
 
 
 
=====Respiratory=====
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
=====Special Senses=====
 
 
 
=====Urogenital=====
 
 
 
=====Miscellaneous=====
 
 
 
<!--Drug Interactions-->
 
|drugInteractions=
 
* Drug
:* Description
 
<!--Use in Specific Populations-->
 
|useInPregnancyFDA=
* '''Pregnancy Category'''
 
|useInPregnancyAUS=
* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''


There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
 
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInLaborDelivery=
|useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
 
|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
|useInNursing=
|useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
|useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
 
|useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
|useInPed=
|useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
 
|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
|useInGeri=
There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
 
|useInGender=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
 
|useInRace=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
 
|useInRenalImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
 
|useInHepaticImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
 
|useInReproPotential=
There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
 
|useInImmunocomp=
There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.


<!--Administration and Monitoring-->
<!--Administration and Monitoring-->
 
|administration=* Oral
|administration=
 
* Oral


* Intravenous
* Intravenous
 
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
|monitoring=
 
There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.


* Description
* Description


<!--IV Compatibility-->
<!--IV Compatibility-->
 
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
|IVCompat=
 
There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.


<!--Overdosage-->
<!--Overdosage-->
|drugBox={{Drugbox2
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 458460406
| IUPAC_name = ''N''-(2-[(5-[(dimethylamino)methyl]furan-2-yl)methylthio]ethyl)-''N'''-methyl-2-nitroethene-1,1-diamine; dimethyl [(5-{[(2-{[1-(methylamino)-2-nitroethenyl]amino}ethyl)sulfanyl]methyl}furan-2-yl)methyl]amine
| image = Ranitidine Structural Formulae.png
| width = 200
| image2 = Ranitidine-A-3D-balls.png


|overdose=
<!--Clinical data-->
| tradename = Zantac
| Drugs.com = {{drugs.com|monograph|ranitidine-hydrochloride}}
| MedlinePlus = a601106
| licence_US = Ranitidine
| pregnancy_AU = B1
| pregnancy_US = B
| legal_AU = S2
| legal_US = OTC/RX
| legal_status = P/POM <small>([[United Kingdom|UK]])</small>
| routes_of_administration = Oral, [[intravenous therapy|IV]]


===Acute Overdose===
<!--Pharmacokinetic data-->
| bioavailability = 39 to 88%
| protein_bound = 15%
| metabolism = [[Liver|Hepatic]]
| elimination_half-life = 2&ndash;3 hours
| excretion = 30&ndash;70% [[Kidney|Renal]]


====Signs and Symptoms====
<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 66357-35-5
| ATC_prefix = A02
| ATC_suffix = BA02
| ATC_supplemental = <br />{{ATC|A02BA|07}} (ranitidine bismuth citrate)
| PubChem = 657345
| IUPHAR_ligand = 1234
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00863
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 571454
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 884KT10YB7
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00422
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 8776
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1790041


* Description
<!--Chemical data-->
 
| C=13 | H=22 | N=4 | O=3 | S=1
====Management====
| molecular_weight = 314.4 g/mol
 
| smiles = [O-][N+](=O)\C=C(\NC)NCCSCc1oc(cc1)CN(C)C
* Description
| InChI = 1/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9-
 
| InChIKey = VMXUWOKSQNHOCA-LCYFTJDEBT
===Chronic Overdose===
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
 
| StdInChI = 1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
 
| StdInChIKey = VMXUWOKSQNHOCA-UHFFFAOYSA-N
<!--Pharmacology-->
}}
 
|mechAction=*  
<!--Drug box 2-->
 
|drugBox=
 
 
 
<!--Mechanism of Action-->
 
|mechAction=
 
*  


<!--Structure-->
<!--Structure-->
 
|structure=*  
|structure=
 
*  


: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]


<!--Pharmacodynamics-->
<!--Pharmacodynamics-->
 
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
|PD=
 
There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.


<!--Pharmacokinetics-->
<!--Pharmacokinetics-->
 
|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
|PK=
 
There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.


<!--Nonclinical Toxicology-->
<!--Nonclinical Toxicology-->
 
|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
|nonClinToxic=
 
There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.


<!--Clinical Studies-->
<!--Clinical Studies-->
 
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
|clinicalStudies=
 
There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.


<!--How Supplied-->
<!--How Supplied-->
 
|howSupplied=*  
|howSupplied=
 
*  


<!--Patient Counseling Information-->
<!--Patient Counseling Information-->
 
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
|fdaPatientInfo=
 
There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.


<!--Precautions with Alcohol-->
<!--Precautions with Alcohol-->
 
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
|alcohol=
 
* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.


<!--Brand Names-->
<!--Brand Names-->
 
|brandNames=* ®<ref>{{Cite web | title =  | url =  }}</ref>
|brandNames=
 
* ®<ref>{{Cite web | title =  | url =  }}</ref>


<!--Look-Alike Drug Names-->
<!--Look-Alike Drug Names-->
 
|lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>
|lookAlike=
 
* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>


<!--Drug Shortage Status-->
<!--Drug Shortage Status-->
|drugShortage=
|drugShortage=
}}
}}
{{LabelImage
|fileName={{PAGENAME}}11.png
}}
{{LabelImage
|fileName={{PAGENAME}}11.png
}}
<small>'''''Synonyms / Brand Names: Ranitidine hydrochloride, Ranitidine HCL, Ranitidine Base, Rantidine HCL, Alquen, Alter-H2, Alvidina, Apo-Ranitidin, Artomil, Azuranit, Coralen, Digestosan, Ergan, Esofex, Fendibina, Gastrial, Gastridina, Gastrolav, Gastrosedol, Kuracid, Label, Lake, Logat, Melfax, Microtid, Mideran, Neugal, Noctone, Noktome, Normon, Novo-Radinine, Nu-Ranit, Pep-Rani, Ptinolin, Quadrin, Quantor, Radin, Ran H2, Ran Lich, Rani 2, Rani AbZ, Rani-BASF, Rani-Puren, Rani-Q, Rani-Sanorania, Rani-nerton, Raniben, Raniberl, Raniberta, Ranibloc, Ranic, Ranicux, Ranidil, Ranidin, Ranidine, Ranidura, Ranifur, Ranigasan, Ranigast, Ranigen, Ranilonga, Ranimerck, Raniogas, Raniplex, Ranisan, Ranitab, Ranitic, Ranitidin, Ranitidin 1A Pharma, Ranitidin AL, Ranitidin AWD, Ranitidin Arcana, Ranitidin Atid, Ranitidin Basics, Ranitidin Duncan, Ranitidin Dyna, Ranitidin Helvepharm, Ranitidin Heumann, Ranitidin Hexal, Ranitidin Merck, Ranitidin Millet, Ranitidin NM, Ranitidin Normon, Ranitidin PB, Ranitidin Stada, Ranitidin von ct, Ranitidin-Cophar, Ranitidin-Isis, Ranitidin-ratiopharm, Ranitidina Tamarang, Ranitidina predilu Grif, Ranitiget, Ranitin, Ranitine, Ranobel, Rantacid, Ranuber, Raticina, Regalil, Renatac, Rozon, Rubiulcer, Santanol, Serviradine, Sostril, Tanidina, Taural, Terposen, Toriol, Trigger, Ulcecur, Ulcex, Ulcirex, Ulcodin, Ulcolind Rani, Ulsaven, Ultidine, Viserul, Zandid, Zantac, Zantac 150, Zantac 75, Zantac In Plastic Container, Zantarac, Zantic
''''' </small>


<!--Pill Image-->
<!--Pill Image-->


{{PillImage
 
|fileName=No image.jpg|This image is provided by the National Library of Medicine.
|drugName=
|NDC=
|drugAuthor=
|ingredients=
|pillImprint=
|dosageValue=
|dosageUnit=
|pillColor=
|pillShape=
|pillSize=
|pillScore=
}}


<!--Label Display Image-->
<!--Label Display Image-->


{{LabelImage
|fileName={{PAGENAME}}11.png|This image is provided by the National Library of Medicine.
}}


{{LabelImage
 
|fileName={{PAGENAME}}11.png|This image is provided by the National Library of Medicine.
 
}}


<!--Category-->
<!--Category-->


[[Category:Drug]]
[[Category:Drug]]

Revision as of 20:43, 4 December 2014

{{DrugProjectFormSinglePage |authorTag=Ammu Susheela, M.D. [1] |genericName=Ranitidine |aOrAn=a |drugClass=antacid |indicationType=treatment |indication=relieves heartburn associated with acid indigestion and sour stomach prevents heartburn associated with acid indigestion and sour stomach brought on by certain foods and beverages |adverseReactions=headache, constipation, diarrhoea, abdominal pain |blackBoxWarningTitle=Title |blackBoxWarningBody=ConditionName:

  • Content


|fdaLIADAdult=* Relieves heartburn associated with acid indigestion and sour stomach

  • Prevents heartburn associated with acid indigestion and sour stomach brought on by certain foods and beverages
  • Ranitidine 150 mg (as ranitidine hydrochloride 168 mg)

|offLabelAdultGuideSupport======Condition1=====

  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Ranitidine (oral) in adult patients.

|offLabelAdultNoGuideSupport======Condition1=====

  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Ranitidine (oral) in adult patients.


|fdaLIADPed======Condition1=====

  • Dosing Information
  • Dosage
Condition2

There is limited information regarding FDA-Labeled Use of Ranitidine (oral) in pediatric patients.


|offLabelPedGuideSupport======Condition1=====

  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Ranitidine (oral) in pediatric patients.

|offLabelPedNoGuideSupport======Condition1=====

  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Ranitidine (oral) in pediatric patients.

|contraindications=* Condition1

|warnings======Allergy alert=====

  • Do not use if you are allergic to ranitidine or other acid reducers
  • Do not use if you have trouble or pain swallowing food, vomiting with blood, or bloody or black stools. These may be signs of a serious condition.
  • with other acid reducers
  • if you have kidney disease, except under the advice and supervision of a doctor
  • Ask a doctor before use if you have
  • frequent chest pain
  • frequent wheezing, particularly with heartburn

unexplained weight loss

  • nausea or vomiting
  • stomach pain

had heartburn over 3 months. This may be a sign of a more serious condition.

  • heartburn with lightheadedness, sweating, or dizziness

chest pain or shoulder pain with shortness of breath; sweating; pain spreading to arms, neck or shoulders; or lightheadedness

  • Stop use and ask a doctor if your heartburn continues or worsens

you need to take this product for more than 14 days

  • If pregnant or breast-feeding, ask a health professional before use.
  • Keep out of reach of children.

|useInPregnancyFDA=* Pregnancy Category |useInPregnancyAUS=* Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Ranitidine (oral) in women who are pregnant. |useInLaborDelivery=There is no FDA guidance on use of Ranitidine (oral) during labor and delivery. |useInNursing=There is no FDA guidance on the use of Ranitidine (oral) with respect to nursing mothers. |useInPed=There is no FDA guidance on the use of Ranitidine (oral) with respect to pediatric patients. |useInGeri=There is no FDA guidance on the use of Ranitidine (oral) with respect to geriatric patients. |useInGender=There is no FDA guidance on the use of Ranitidine (oral) with respect to specific gender populations. |useInRace=There is no FDA guidance on the use of Ranitidine (oral) with respect to specific racial populations. |useInRenalImpair=There is no FDA guidance on the use of Ranitidine (oral) in patients with renal impairment. |useInHepaticImpair=There is no FDA guidance on the use of Ranitidine (oral) in patients with hepatic impairment. |useInReproPotential=There is no FDA guidance on the use of Ranitidine (oral) in women of reproductive potentials and males. |useInImmunocomp=There is no FDA guidance one the use of Ranitidine (oral) in patients who are immunocompromised.

|administration=* Oral

  • Intravenous

|monitoring=There is limited information regarding Monitoring of Ranitidine (oral) in the drug label.

  • Description

|IVCompat=There is limited information regarding IV Compatibility of Ranitidine (oral) in the drug label.

|drugBox={{Drugbox2 | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 458460406 | IUPAC_name = N-(2-[(5-[(dimethylamino)methyl]furan-2-yl)methylthio]ethyl)-N'-methyl-2-nitroethene-1,1-diamine; dimethyl [(5-{[(2-{[1-(methylamino)-2-nitroethenyl]amino}ethyl)sulfanyl]methyl}furan-2-yl)methyl]amine | image = Ranitidine Structural Formulae.png | width = 200 | image2 = Ranitidine-A-3D-balls.png

| tradename = Zantac | Drugs.com = Monograph | MedlinePlus = a601106 | licence_US = Ranitidine | pregnancy_AU = B1 | pregnancy_US = B | legal_AU = S2 | legal_US = OTC/RX | legal_status = P/POM (UK) | routes_of_administration = Oral, IV

| bioavailability = 39 to 88% | protein_bound = 15% | metabolism = Hepatic | elimination_half-life = 2–3 hours | excretion = 30–70% Renal

| CASNo_Ref =  ☑Y | CAS_number_Ref =  ☑Y | CAS_number = 66357-35-5 | ATC_prefix = A02 | ATC_suffix = BA02 | ATC_supplemental =
A02BA07 (WHO) (ranitidine bismuth citrate) | PubChem = 657345 | IUPHAR_ligand = 1234 | DrugBank_Ref =  ☑Y 

| DrugBank = DB00863

| ChemSpiderID_Ref =  ☑Y | ChemSpiderID = 571454 | UNII_Ref =  ☑Y | UNII = 884KT10YB7 | KEGG_Ref =  ☑Y | KEGG = D00422 | ChEBI_Ref =  ☒N | ChEBI = 8776 | ChEMBL_Ref =  ☒N | ChEMBL = 1790041

| C=13 | H=22 | N=4 | O=3 | S=1 | molecular_weight = 314.4 g/mol | smiles = [O-][N+](=O)\C=C(\NC)NCCSCc1oc(cc1)CN(C)C | InChI = 1/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9- | InChIKey = VMXUWOKSQNHOCA-LCYFTJDEBT | StdInChI_Ref =  ☒N | StdInChI = 1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3 | StdInChIKey_Ref =  ☒N | StdInChIKey = VMXUWOKSQNHOCA-UHFFFAOYSA-N }} |mechAction=*

|structure=*

File:Ranitidine (oral)01.png
This image is provided by the National Library of Medicine.

|PD=There is limited information regarding Pharmacodynamics of Ranitidine (oral) in the drug label.

|PK=There is limited information regarding Pharmacokinetics of Ranitidine (oral) in the drug label.

|nonClinToxic=There is limited information regarding Nonclinical Toxicology of Ranitidine (oral) in the drug label.

|clinicalStudies=There is limited information regarding Clinical Studies of Ranitidine (oral) in the drug label.

|howSupplied=*

|fdaPatientInfo=There is limited information regarding Patient Counseling Information of Ranitidine (oral) in the drug label.

|alcohol=* Alcohol-Ranitidine (oral) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

|brandNames=* ®[1]

|lookAlike=* A® — B®[2]

|drugShortage= }} {{#subobject: 

 |Label Page=Ranitidine (oral)
 |Label Name=Ranitidine (oral)11.png

}}

{{#subobject: 

 |Label Page=Ranitidine (oral)
 |Label Name=Ranitidine (oral)11.png

}}

Synonyms / Brand Names: Ranitidine hydrochloride, Ranitidine HCL, Ranitidine Base, Rantidine HCL, Alquen, Alter-H2, Alvidina, Apo-Ranitidin, Artomil, Azuranit, Coralen, Digestosan, Ergan, Esofex, Fendibina, Gastrial, Gastridina, Gastrolav, Gastrosedol, Kuracid, Label, Lake, Logat, Melfax, Microtid, Mideran, Neugal, Noctone, Noktome, Normon, Novo-Radinine, Nu-Ranit, Pep-Rani, Ptinolin, Quadrin, Quantor, Radin, Ran H2, Ran Lich, Rani 2, Rani AbZ, Rani-BASF, Rani-Puren, Rani-Q, Rani-Sanorania, Rani-nerton, Raniben, Raniberl, Raniberta, Ranibloc, Ranic, Ranicux, Ranidil, Ranidin, Ranidine, Ranidura, Ranifur, Ranigasan, Ranigast, Ranigen, Ranilonga, Ranimerck, Raniogas, Raniplex, Ranisan, Ranitab, Ranitic, Ranitidin, Ranitidin 1A Pharma, Ranitidin AL, Ranitidin AWD, Ranitidin Arcana, Ranitidin Atid, Ranitidin Basics, Ranitidin Duncan, Ranitidin Dyna, Ranitidin Helvepharm, Ranitidin Heumann, Ranitidin Hexal, Ranitidin Merck, Ranitidin Millet, Ranitidin NM, Ranitidin Normon, Ranitidin PB, Ranitidin Stada, Ranitidin von ct, Ranitidin-Cophar, Ranitidin-Isis, Ranitidin-ratiopharm, Ranitidina Tamarang, Ranitidina predilu Grif, Ranitiget, Ranitin, Ranitine, Ranobel, Rantacid, Ranuber, Raticina, Regalil, Renatac, Rozon, Rubiulcer, Santanol, Serviradine, Sostril, Tanidina, Taural, Terposen, Toriol, Trigger, Ulcecur, Ulcex, Ulcirex, Ulcodin, Ulcolind Rani, Ulsaven, Ultidine, Viserul, Zandid, Zantac, Zantac 150, Zantac 75, Zantac In Plastic Container, Zantarac, Zantic

  1. ↑ Empty citation (help)
  2. ↑ "http://www.ismp.org". External link in |title= (help)
Retrieved from "https://www.wikidoc.org/index.php?title=Ranitidine_(oral)&oldid=1045214"